George Church’s New Startup Engineers AAV Vectors that Evades Host Immune Responses
Adeno-associated viral (AAV) vectors are widely used in vivo therapeutic gene delivery vehicles. The many advantages they provide, including safety, broad tissue tropism, lack of pathogenicity, and efficient and persistent gene transfer, have made them the "gold standard" for gene therapies.
GO Prime with only $1.49 now
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115